13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • ASCOLT

    Acronym: 

    ASCOLT

    ACTRN/NCT /ethics: 

    NCT00565708

    Scientific title: 

    Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

    Summary of trial and patient characteristics

    Cancer Type Bowel and colon
    Trial Type Treatment
    Phase Phase III Tumour Stream Bowel and Colon
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2018-12-01
    Molecular Target Anticipated End Date
    Cancer Type Bowel and colon
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Bowel and Colon
    Cancer Stage All stages
    Anticipated Start Date 2018-12-01
    Anticipated End Date

    Trial Summary

    We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally. STUDY OBJECTIVE To assess the effectiveness of Aspirin against placebo control in patients with dukes C or high risk dukes B colorectal cancer in terms of Disease Free Survival (DFS) and Overall Survival (OS)

    Lay Summary

    Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Lyell McEwin Hospital Andy Phay andy.phay@sa.gov.au 08 8282 0833 Professor Tim Price Recruiting